The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

ACT EU has developed the guideline to simplify the clinical trials application package for use during PHEs. The package consists of:

1️⃣ A guidance document on the simplified application package for clinical trials targeting a PHE
2️⃣ Annex I: Part I language requirements
3️⃣ Annex II: Part II national requirements
4️⃣ A site suitability template

In preparation for publication, stakeholders are invited to review the documents and provide targeted feedback only on any critical issues identified on:

➡️ Clarity and usability of the guidance and templates;
➡️ Issues that may affect the practical applicability of the documents

🔴 HOW TO SUBMIT: Please submit any comments by 24 June COB to “romee.reijsenbachdehaan@ema.europa.eu“, copying “acteu@ema.europa.eu

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70